PLK1 and osteosarcoma: More importantly, we confirmed that Volasertib, a frontline clinical candidate of PLK1 inhibitor, is effective in suppressing the growth of multiple osteosarcoma cell lines in vitro as well as the development of tumors in the patient-derived xenograft (PDX) models in vivo by disrupting the cell cycle and triggering apoptosis.